Characterization of early plasma concentrations of midazolam in pigs after administration by an autoinjector

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 7, 2004, Pages 297-301

  Levy, Aharon ^a   Kushnir, Moshe ^a   Chapman, Shira ^a   Brandeis, Rachel ^a   Teitelbaum, Zvi ^a   Gilat, Eran ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Anticonvulsants; Benzodiazepines; Organophosphates; Sedation; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; ATROPINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; MIDAZOLAM; ORGANOPHOSPHATE; OXIME; WATER;

ACCELERATION; ANIMAL EXPERIMENT; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; INTOXICATION; MUSCLE RELAXATION; NONHUMAN; SEIZURE; SELF INJECTION; SWINE; TIME;

ANIMALS; AREA UNDER CURVE; INJECTIONS; MIDAZOLAM; SWINE;

EID: 6444225015     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.417     Document Type: Article

References (19)

1. Levy A, Cohen G, Gilat E, et al. Therapeutic versus prophylactic treatment strategies against nerve-agent induced brain injuries. In Proceedings of Medical Defense Bioscience Reviews. US-AMRMC: Baltimore, 2000; 280-290.
2. Kawana N, Ishimatsu S, Kanda K. Psycho-physiological effects of the terrorist sarin attack on the Tokyo subway system. Mil Med 2001; 166: 23-26.
3. Kadar T, Cohen G, Sahar R, Alkalai D, Shapira S. Long-term study of brain lesions following soman, in comparison to DFP and metrazol poisoning. Human Exp Toxicol 1992; 11: 517-523.
4. Kadar T, Shapira S, Cohen G, Sahar R, Alkalay D, Raveh L. Sarin-induced neuropathology in rats. Human Exp Toxicol 1995; 14: 252-259.
5. Petras JM. Neurology, neuropathology of soman-induced brain injury: an overview. J Exp Anal Behav 1994; 61: 319-329.
6. Hung OR, Dyck JB, Varvel J, Shafer SL, Stanski DR. Comparative absorption kinetics of intramuscular midazolam and diazepam. Can J Anaesth 1996; 43: 450-455.
7. Nordt SP, Clark RF. Midazolam: a review of therapeutic use and toxicity. J Emerg Med 1997; 15: 357-365.
8. Lacoste L, Bouquet S, Ingrand P, Caritez JC, Carretier M, Debaene B. Intranasal midazolam in piglets: pharmacodynamics and pharmacokinetics with bioavailability determination. Lab Anim 2000; 34: 29-35.
9. Gilat E, Goldman M, Lahat E, et al. Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pig. Arch Toxicol 2003; 77: 167-172.
10. McDonough JH, McMonagle J, Copeland T, Zoeffel D, Shih TM. Comparative evaluation of benzodiazepines for control of soman-induced seizures. Arch Toxicol 1999; 73: 473-478.
11. McDonough JH, Capacio BR, Shih TM. Benzodiazepine dosage necessary to terminate soman-induced seizures in a Rhesus monkey model. Proceedings of the Medical Defense Bioscience Reviews. US-AMRMC: Baltimore, 2000; 269-278.
12. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998; 101: 33-37.
13. Martin TR, Kastor JA, Kershbaum KL, Engelman K. The effects of atropine administered with standard syringe and self injector device. Am Heart J 1980; 99: 282-288.
14. Friedl KE, Hannan CJ, Schadler PW, Jacob WH. Atropine absorption after intramuscular administration with 2-pralidoxime chloride by two automatic injector devices. J Pharmac Sci 1989; 78: 728-731.
15. Nyberg AG, Cassel G, Jeneskog T, et al. Pharmacokinetics of HI-6 and atropine in anaesthetized pigs after administration by a new autoinjector. Biopharm Drug Dispos 1995; 16: 635-651.
16. Citron NM, Chen YM. A sensitive radioreceptor assay for determining scopolamine concentrations in plasma and urine. J Pharm Sci 1987; 76: 328-332.
17. McDonough JH, Shih TM. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci Biobehav Rev 1997; 21: 559-579.
18. Behne M, Janshon G, Asskali F, Forster H. The pharmacokinetics of midazolam following intramuscular administration. Anaesthesist 1989; 38: 268-274.
19. Rey E, Treluyer JM, Pons G. Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Clin Pharmacokinet 1999; 36: 409-424.